Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab Combined With Becotatugvedotin in Advanced Cholangiocarcinoma
NCT07514533Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab and cofetuzumab pelidotin in cholangiocarcinoma (CCA), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Objective Response Rate at 2 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
pucotenlimabcofetuzumab pelidotin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07514533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514533.